Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

32.61USD
4:02pm EDT
Change (% chg)

$0.09 (+0.28%)
Prev Close
$32.52
Open
$32.55
Day's High
$32.80
Day's Low
$32.30
Volume
1,812,450
Avg. Vol
1,746,434
52-wk High
$56.44
52-wk Low
$27.59

Select another date:

Thu, Jun 22 2017

BRIEF-Wockhardt, units settle commercial litigation with Teva Pharma, Cephalon

* Says co, units settle with teva and its affiliate a commercial litigation in high court, london

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

GSK wins $235 million from Teva in Coreg patent trial

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

GSK wins $235 million from Teva in Coreg patent trial

June 21 A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

Israeli credit card firm Isracard names outgoing Teva CFO as chairman

TEL AVIV, June 21 Israel's biggest credit card company Isracard on Wednesday named Eyal Desheh, the outgoing chief financial officer of Teva Pharmaceutical Industries , as its new chairman.

BRIEF-Teva Pharmaceuticals USA says recalls one lot of Paliperidone ER tablets

* Teva Pharmaceuticals USA Inc initiated a voluntary recall to retail-level for one lot of paliperidone extended-release tablets, 3mg, 90 count bottles

BRIEF-Mylan says Teva's expression of interest was simply not right for Mylan and its stakeholders

* Mylan's letter to shareholders dated june 12 says Teva’s expression of interest was simply not right for Mylan and its stakeholders

BRIEF-Teva Pharmaceutical announces launch of generic Zetia in U.S.

* Teva announces launch of generic Zetia® in the United States

Teva Pharm looks to refresh board with four new nominees

* Israel's Teva Pharmaceutical Industries is looking to refresh its board of directors with four new members as it tries to restore investor confidence after a series of missteps.

BRIEF-Teva announces exclusive launch of Generic Pataday in the United States

* Teva announces exclusive launch of Generic Pataday® in the United States

Select another date:

More From Around the Web